Q-omics provides the consensus-scored RASAL1 profile across patient tissues and cancer cell-line models. RASAL1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RASAL1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RASAL1 protein abundance shows 22,940 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where RASAL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASAL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASAL1 survival associations across molecular data types. RASAL1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASAL1 RNA expression–survival associations across cancer types. High RASAL1 expression shows unfavorable associations in UCEC, OV and PAAD, but favorable associations in THCA, HNSC and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RASAL1 RNA expression.
This table summarizes RASAL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RASAL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASAL1 shows lower tumor expression in HNSC, KICH, KIRC and BRCA and higher tumor expression in LUAD and LUSC. The HNSC box plot shows higher RASAL1 RNA expression in normal versus tumor tissue (log2 FC = −1.519, t-test p < 0.001).
This table shows molecular features associated with RASAL1 in patient tissues and cancer cell lines. In patient samples, RASAL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RASAL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
